Cancer Vaccines Measuring Market Potential

Questions: Discounts, Updates etc.

Pages: 232

Price (Single): $1500

Price (Departmental): $2999

Price (Company): $4999

Publication Date: 2004-10-01

Order Online Now

Name:
Email:
Company Name:
Telephone:
Licence Type:
Payment Method:

People that purchased this report also purchased:

Contact LeadDiscovery

If you have questions about this report
To find out if you qualify for a discount
Want a more up to date version
Can't find a report that meets your needs

Search all reports

Overview

This report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets. Vaccine product candidates are discussed within the context of the disease areas they are attempting to penetrate and include: melanoma, prostate cancer, colorectal cancer, lung cancer, breast cancer, and pancreatic cancer.

There are currently over twenty Phase III trials ongoing for various indications and new approvals may come as early as 2005. The value of the market for cancer vaccines has the potential to reach $6 billion by 2010.

This report is designed to provide the information, insight and analysis key to an understanding of how cancer vaccines will impact the biotech and pharmaceutical marketplace. Those in the field of cancer therapy and cancer vaccines will want to read this report in order to better understand where and how vaccines will make a difference in future cancer therapy.

This 232-page report:

Gauges the potential of key vaccine products nearing commercialization.

Analyzes the results of key clinical trials as a means of determining future success in the market.

Forecasts financial growth of the cancer vaccine market through 2010.

Assesses the competition from cytotoxics and other biologics in six key cancer markets.

Provides valuable data concerning patient populations, survival rates, and global epidemiology

Identifies and discusses trends and issues that will have a significant impact on the cancer vaccine market.

Profiles the leading companies in the field and provides valuable information and analysis concerning their lead vaccine candidates.

Table of Contents
1 Methodology and Executive Summary
Table 1.1 Value of the Cancer Vaccine Market, by Type, 2010
- 2 The Global Impact of Cancer
  - 2.1 United States
Table 2.1 Estimated New Cancer Cases and Deaths, US 2004
Graph 2.1 Deadliest Cancers in the US 2004
Graph 2.2 Leading Sites of New Cancer Cases, Male 2004
Graph 2.3 Leading Sites of New Cancer Cases, Female 2004
Table 2.2 Total Incidence of Cancer, by Region 2000
Graph 2.4 Regions Most-Effected by Cancer, 2000
Table 2.3 Rates of Incidence and Deaths for Select Cancers Worldwide, 2000
Table 2.4 Five-Year Survival Rates for Select Cancers by Stage at Diagnosis, US 2000
Table 2.5 The Economic Impact of Cancer in the US
Table 2.6 Global Lung Cancer Incidence in Select Regions, 2000
Graph 2.5 Global Prostate Cancer Incidence, Select Regions, 2000
Table 2.7 Breast Cancer Survival Rates, by Stage
Table 2.8 Breast Cancer Overall Survival Rate
Graph 2.6 Pancreatic Cancer Incidence, Select Regions, 2000
Graph 2.7 Incidence of Melanoma, US vs. Rest of World, 2000
- 3 Introduction to Cancer Vaccines
  - 3.1 The Immune System and Cancer
  - 3.2 The Basics
  - 3.3 Unmet Need in Cancer Therapy
  - 3.4 Why Vaccines?
  - 3.5 Early Efforts at Cancer Vaccines
  - 3.6 Types of Vaccines
    - 3.6.1 Viral Vectors and DNA Vaccines
    - 3.6.2 Antigen/adjuvant Vaccines
    - 3.6.3 Whole-cell Tumor Vaccines
    - 3.6.4 Anti-Idiotype Vaccines
    - 3.6.5 Dendritic Cell Vaccines
Table 3.1 Key Vaccines Nearing FDA Approval
- 4 Vaccines and the Future of the Colorectal Cancer Therapy Market
  - 4.1 Current Treatment of Colorectal Cancer
Table 4.1 The Stages of Colorectal Cancer
Table 4.2 Leading Drugs for Treatment of Colorectal Cancer
Table 4.3 Sales of New Biologic Therapies for Colorectal Cancer 2004
Graph 4.1 Growth of the Colorectal Cancer Therapy Market, 2000-2004
Graph 4.2 The Colorectal Cancer Therapy Market, Cytotoxics vs. Biologics 2004
Table 4.4 Therapeutic Vaccine Pipeline for Colorectal Cancer
Graph 4.3 Therapeutic Vaccines for Colorectal Cancer, by Clinical Trial Phase
Table 4.5 Oncovax Sales Forecast 2005-2010 ($ mn)
- 5 Vaccines and the Future of Prostate Cancer Therapy
  - 5.1 Current Treatment of Prostate Cancer
Table 5.1 The Stages of Prostate Cancer
Table 5.2 Best-Selling Hormone Therapies for Prostate Cancer
Table 5.3 Leading Drugs for Treatment of Prostate Cancer
Graph 5.1 Value of the Prostate Therapy Market 2000-2003
Table 5.4 Therapeutic Vaccine Pipeline for Prostate Cancer
Graph 5.2 Therapeutic Vaccines for Prostate Cancer, by Clinical Trial Phase
Table 5.5 Prostate Cancer Vaccines Sales Forecast 2006-2010
Graph 5.3 Prostate Cancer Vaccine Market Share 2007
Graph 5.4 Prostate Cancer Vaccine Market Share 2010
- 6 Vaccines and the Future of the Lung Cancer Therapy Market
  - 6.1 Current Treatment of Lung Cancer
Table 6.1 Stages of Lung Cancer
Table 6.2 Leading Drugs for Treatment of Lung Cancer
Graph 6.1 Value of the Lung Cancer Therapy Market 2000-2003
Table 6.3 Major Uses for Popular Anti-Cancer Agents
Table 6.4 Sales of New Targeted Therapies for Lung Cancer 2004
Table 6.5 Therapeutic Vaccine Pipeline for Lung Cancer
Graph 6.2 Therapeutic Vaccines for Lung Cancer, by Clinical Trial Phase
Table 6.6 Lung Cancer Vaccines Sales Forecast 2006-2010
Graph 6.3 Lung Cancer Vaccine Market Share 2007
Graph 6.4 Lung Cancer Vaccine Market Share 2010
- 7 Vaccines and the Future of Breast Cancer Therapy
  - 7.1 Current Treatment of Breast Cancer
Table 7.1 Stages of Breast Cancer
Table 7.2 Leading Drugs for Treatment of Breast Cancer
Graph 7.1 Breast Cancer Therapies Market Share 2003
Table 7.3 Therapeutic Vaccine Pipeline for Lung Cancer
Graph 7.2 Therapeutic Vaccines for Breast Cancer, by Clinical Trial Phase
Table 7.4 Breast Cancer Vaccines Sales Forecast 2007-2011
- 8 Vaccines and the Future of Pancreatic Cancer Therapy
  - 8.1 Current Treatment of Pancreatic Cancer
Table 8.1 Stages of Pancreatic Cancer
Table 8.2 Biologics in Clinical Development for Pancreatic Cancer
Table 8.3 Leading Drugs for Treatment of Pancreatic Cancer
Table 8.4 Therapeutic Vaccine Pipeline for Pancreatic Cancer
Graph 8.1 Therapeutic Vaccines for Pancreatic Cancer, by Clinical Trial Phase
Table 8.5 Pancreatic Vaccine Approvals and Their Initial Indications
Table 8.6 Pancreatic Cancer Vaccines Sales Forecast 2006-2010
- 9 Vaccines and the Future of Melanoma Therapy
  - 9.1 Current Treatment of Melanoma
Table 9.1 Stages of Melanoma
Table 9.2 Currently Available Biological Therapies for Melanoma
Table 9.3 Single-Agent Cytotoxics for Melanoma
Table 9.4 Leading Drugs for Treatment of Melanoma
Table 9.5 Therapeutic Vaccine Pipeline for Melanoma
Table 9.6 Competition in the Melanoma Therapy Market
Table 9.7 Melanoma Vaccines Sales Forecast 2006-2010
- 10 Company Briefs
Aastrom Biosciences
Advaxis
Table 10.1 Advaxisï¿½ Cancer Vaccine Pipeline
AlphaVax
Antigenics
Table 10.2 Clinical Development Status of Oncophage
Aphton Corporation
Aventis Pasteur
AVI Biopharma
Biomira
Table 10.3 Biomiraï¿½s Vaccine Pipeline
Biovex
CancerVax Corporation
Cell Genesys
Table 10.4 Clinical Development of GVAX
Corixa
Cytogen Corporation
Dendreon
Table 10.5 Dendreonï¿½s Vaccine Pipeline
Epimmune
Favrille Inc.
GeneMax
Genitope Corporation
Genzyme (Oncology)
Table 10.6 Genzymeï¿½s Vaccine Pipeline
Geron Corporation
GlaxoSmithKline Biologicals
IDM, Inc.
Table 10.7 IDMï¿½s Vaccine Pipeline
Igeneon
Table 10.8 Igeneonï¿½s Vaccine Pipeline
ImClone Systems Incorporated
Intracel Holdings Corporation
Large Scale Biology Corporation
Lorus Therapeutics
Maxygen
MedImmune
Merck & Co.
Northwest Biotherapeutics
Oxford BioMedica plc
Pharmexa A/S
Table 10.9 Pharmexaï¿½s Cancer Vaccine Pipeline
Progenics Pharmaceuticals
Table 10.10 Progenicsï¿½ Cancer Vaccine Pipeline
Therion Biologics Corporation
Table 10.11 Therionï¿½s Cancer Vaccine Pipeline
Transgene S.A.
United Biomedical
Vical Incorporated
Xcyte Therapies Inc.
Table 10.12 Xcyte Therapies Vaccine Pipeline
YM Biosciences Inc.
Zycos
Appendix
Table I Cancer Vaccines in Clinical Development
Table II Anticipated Launches of Emerging Cancer Vaccines
Graph I Vaccines in Preclinical to Phase III Development Stages, by Indication
Graph II Leading Companies in Field of Cancer Vaccines
Graph III Number of Vaccine Indications in Clinical Trials, by Phase
Graph IV Leading Cancer Indications for Vaccines
Graph V Vaccines with Greatest Number of Potential Indications

Other users found this report page using the following search terms: cancer vaccine oncology Dendritic Cell cervical cancer melanoma cancer market vaccines potential graphs vaccine pancreatic lung prostate graph

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Cancer Vaccines Measuring Market Potential

Credit Card Details

Invoice Details

Overview

Table of Contents